Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins

Inclusion Criteria:

- Diagnosis of cerebral cavernous malformations-common Hispanic mutation (CCM1-CHM)

- Must be willing to travel to the University of New Mexico in Albuquerque, NM for 5
visits over the course of three months.

- Indication for statin treatment based on the National Cholesterol Education Program
(NCEP) ATPIII Guidelines:

- LDL greater than or equal to 160.

- LDL of 130-159 AND two or more risk factors (e.g., cigarette smoking, hypertension,
low HDL cholesterol) AND 10-year coronary heart disease (CHD) risk or 10-20%.

- LDL of 101-159 AND coronary heart disease, diabetes mellitus, symptomatic carotic
artery disease, peripheral arterial disease, or abdominal aortic aneurysm OR 10-year
CHD equivalent risk > 20%.

Exclusion Criteria:

- Incarceration

- Unable to pass MRI safety screening (pregnant females, claustrophics, or those with
certain metallic items implanted in their bodies)

- Low kidney function or transplants, an eGFR below 60 mL/min

- Currently taking statin medications or have taken statin medications in the past 6
months

- Known allergy or intolerance to statins

- Known allergy or intolerance to gadolinium

- Liver dysfunction at baseline, AST > 47 and/or ALT > 49

- Consumption of large quantities of alcohol, men who consume more than 2 daily drinks
and women who consume more than one daily drink

- CK level of 232 or higher

- Triglycerides greater than or equal to 500.

- Medications: gemfibrozil, cyclosporine, danazol, itraconazole, ketoconazole,
posaconazole, ethromycin, clarithomycin, telithromycin, HIV protease inhibitors,
nefazoldone, amiodarone, verapamil, dilitiazem, amlodipine, or ranalazine